Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced positive preclinical data for its OMV based Lyme disease vaccine. Publication of this study in the peer reviewed scientific journal Vaccine titled “Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis” describes the pre-clinical data of the candidate Lyme vaccine based on Intravacc’s OMV platform. This study shows that OMV’s expressing Borrelia (lipo)
Currently, no vaccine against Lyme disease, the fastest growing and most common tick-borne illness in North America and Europe, is available for humans. If untreated, symptoms may include loss of the ability to move one or both sides of the face, joint pains, severe headaches with neck stiffness, or heart palpitations. Antibiotics are the primary treatment and are usually successful, but only when given in time. A vaccine would limit the use of antibiotics and the potential rise of antibiotic resistance.
Safety evidence of OMV’s
Vaccination of animals has shown that Intravacc’s OMV-based vaccines can protect against various pathogens. Toxicology studies with various OMV-based vaccines showed no tissue and organ damage in the animals. OMV based meningococcal vaccine phase I and II studies have shown that they are safe in both children and adults. Today one OMV-based vaccine has been approved by the EMA and is on the market.
The study conducted in collaboration with the Amsterdam Medical Center in the Netherlands evaluated Intravacc’s genetically modified meningococci, resulting in bacteria producing immunogenic vesicles (OMV) expressing Lyme lipoprotein OspA on the surface of these vesicles. Groups of eight mice were vaccinated at day zero, 14 and 28 with either 40 µg OMVs, expressing OspA and the control group received the same amount of empty OMV’s.
To measure the protection after vaccination, animals were infected with live Borrelia burgdorferi by needle injection on day 42 and on day 62 all mice were sacrificed, and blood and organs were collected and tested for the presence of borrelia by culture and DNA testing. At the same time points, blood samples were collected from all the animals. Strong antibody responses were induced in animals that received OMV-OspA. Whereas in the control group no borrelia specific antibodies were detected. In the skin of one of the eight animals, life bacteria were detected. Traces of Borrelia specific DNA were detected in one to two animals.
This study shows that OMV-based vaccines expressing Borrelia (lipo)
Dr. Jan Groen, Intravacc’s CEO, said:
“This is yet another proof that our OMV platform is versatile and effective in addressing a variety of diseases. We show that it is possible to couple OMV to external antigens and that the bacterium can also be modified to express the antigens. In addition to the great results shown for Lyme disease, the platform can be utilized for vaccine development for virtually any disease.”